The real burden of CSU symptoms
For 400,000+ patients with chronic spontaneous urticaria (CSU) who are taking antihistamines, uncontrolled symptoms are the source of their unseen stories.1
Many patients with CSU are symptomatic on antihistamines and frustrated by their condition2,3
In CSU, there’s a control gap: ~50% of patients remain symptomatic despite taking increased doses of antihistamines2
After increasing the dosage of antihistamines, there are few additional options for CSU to suit patient needs4
CSU might not be life-threatening, but it is often debilitating5
†This real-world study assessed the burden of CSU in 673 diagnosed patients whose symptoms persisted for ≥12 months despite treatment.7
How does real-world CSU management align with urticaria treatment guidelines?
References:
1. Data on file. IQVIA LAAD APLD, extracted by NVS Global Business Solutions. Novartis Pharmaceuticals Corp; May 2023.
2. Kaplan A, Lebwohl M, Giménez-Arnau AM, Hide M, Armstrong AW, Maurer M. Allergy. 2023;78(2):389–401. doi:10.1111/all.15603
3. Goldstein S, Eftekhari S, Mitchell L, et al. Acta Derm Venereol. 2019;99(12):1091–1098. doi:10.2340/00015555-3282
4. Zuberbier T, Latiff AHA, Abuzakouk M, et al. Allergy. 2022;77(3):734–766. doi:10.1111/all.15090
5. Sánchez-Borges M, Ansotegui IJ, Baiardini I, et al. World Allergy Organ J. Published online June 1, 2021. 2021;14(6):100533. doi:10.1016/j.waojou.2021.100533
6. Balp M-M, Krupsky K, Balkaran BL, et al. Oral presentation at: European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023; June 9–11, 2023; Hamburg, Germany.
7. Maurer M, Abuzakouk M, Bérard F, et al. Allergy. 2017;72(12):2005–2016. doi:10.1111/all.13209